» Articles » PMID: 23948108

Impact of Atrial Fibrillation on Early Complications and One Year-survival After Cardioverter Defibrillator Implantation: Results from the German DEVICE Registry

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2013 Aug 17
PMID 23948108
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Aims And Objective: Outcome data of patients with implantable cardioverter defibrillators (ICD) and atrial fibrillation (AF) are conflicting. The German DEVICE registry aims to add further information on this particular cohort.

Methods And Results: The German DEVICE registry is a nationwide prospective multicenter database of ICD implantations. 3261 patients are included (81% males, 2701 (82.8%) first ICD implantations, 560 (17.2%) ICD replacements). Cardiac resynchronization therapy (CRT-D) was performed in 882 patients (27.0%). Sinus rhythm (SR) was present in 2654 (81.4%) and atrial fibrillation (AF) in 607 (18.6%). Left ventricular ejection fraction (LVEF) did not differ between groups (SR 32.3%, AF 30.4%; p = 0.09). AF patients were older (AF 70.9 versus SR 63.9 years; p < 0.0001), presented with more co-morbidities (diabetes, hypertension, chronic kidney disease; all p < 0.001). In-hospital complications were not significantly different between groups (p = 0.58). Follow-up information after one year was available in 2967 patients (91%). One-year overall mortality after first ICD implantation was 4.9% for SR and 11.2% for AF patients (p < 0.0001); mortality one year after ICD replacement was 8.4% for SR and 12.0% for AF (p = 0.34). No statistically significant difference between SR and AF patients receiving a CRT device was observed (SR 6.9%, AF 10.7%, p = 0.16) in terms of one-year mortality.

Conclusion: The German DEVICE registry demonstrates that patients with AF who receive ICD devices are older, have more co-morbidity and more severe heart failure. AF carries an independent 1.39 fold risk (95% CI 1.02-1.89) of death after one year in patients only with first ICD implantation.

Citing Articles

Impact of atrial fibrillation on 1-year outcome in patients with implantable cardioverter defibrillator or cardiac resynchronization therapy with defibrillator: results from the German DEVICE Registry.

Feickert S, Ewertsen N, Kobe J, Kleemann T, Jehle J, Senges J J Thorac Dis. 2024; 16(3):1825-1835.

PMID: 38617758 PMC: 11009579. DOI: 10.21037/jtd-23-274.


Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial.

Knops R, Pepplinkhuizen S, Delnoy P, Boersma L, Kuschyk J, El-Chami M Eur Heart J. 2022; 43(47):4872-4883.

PMID: 36030464 PMC: 9748587. DOI: 10.1093/eurheartj/ehac496.


Predictors of rhythm outcomes after cardiac resynchronization therapy in atrial fibrillation patients: When should we use an atrial lead?.

Nedios S, Doering M, Darma A, Lucas J, Dinov B, Arya A Clin Cardiol. 2020; 44(2):210-217.

PMID: 33295029 PMC: 7852157. DOI: 10.1002/clc.23527.


Outcomes of cardiac resynchronisation therapy in patients with heart failure with atrial fibrillation: a systematic review and meta-analysis of observational studies.

Mustafa U, Atkins J, Mina G, Dawson D, Vanchiere C, Duddyala N Open Heart. 2019; 6(1):e000937.

PMID: 31217991 PMC: 6546263. DOI: 10.1136/openhrt-2018-000937.


Atrial Fibrillation Is Associated With Higher Overall Mortality in Patients With Implantable Cardioverter-Defibrillator: A Systematic Review and Meta-Analysis.

Mustafa U, Dherange P, Reddy R, DeVillier J, Chong J, Ihsan A J Am Heart Assoc. 2018; 7(22):e010156.

PMID: 30554547 PMC: 6404454. DOI: 10.1161/JAHA.118.010156.